Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 6/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TNF | P01375 | 2/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27093964 | 1.00 | TLR2 (0.62) | TLR2KMT2ATNFPTPN1CASP3 | |
| SCHEMBL30434908 | 0.96 | TLR2 (0.57) | TLR2KMT2ATNFPTPN1CASP3 | |
| SCHEMBL7713440 | 0.96 | TLR2 (0.57) | TLR2KMT2ATNFPTPN1CASP3 | |
| SCHEMBL38664780 | 0.92 | TLR2 (0.54) | TLR2KMT2ATNFPTPN1CASP3 | |
| SCHEMBL27353250 | 0.91 | TLR2 (0.59) | TLR2TNF | |
| SCHEMBL16327986 | 0.89 | TLR2 (0.59) | TLR2TNF | |
| SCHEMBL7208037 | 0.88 | TLR2 (0.54) | TLR2KMT2ATNFPTPN1CASP3 | |
| SCHEMBL30919288 | 0.87 | KMT2A (0.54) | TLR2KMT2APTPN1CASP3 | |
| SCHEMBL4300738 | 0.87 | KMT2A (0.58) | TLR2KMT2APTPN1CASP3 | |
| SCHEMBL20504185 | 0.87 | KMT2A (0.58) | TLR2KMT2APTPN1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398962-A1 | DENDRIMER-GLUTAMINE ANTAGONIST CONJUGATES AND METHODS OF USE THEREOF | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY (CZ) | 2024-12-05 | — | — | US | disclosed |
| EP-4322961-A1 | DENDRIMER-GLUTAMINE ANTAGONIST CONJUGATES AND METHODS OF USE THEREOF | The Johns Hopkins University (US) | 2024-02-21 | — | — | EP | disclosed |
| WO-2022221490-A1 | DENDRIMER-GLUTAMINE ANTAGONIST CONJUGATES AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240398962-A1 | DENDRIMER-GLUTAMINE ANTAGONIST CONJUGATES AND METHODS OF USE THEREOF | GLUL, GLS, GRM2 | TLR2 164/4885KMT2A 398/4885TNF 1913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.